Media Articles Related to Sprycel (Dasatinib)
Halting lethal childhood leukemia
Source: Genetics News From Medical News Today [2017.01.10]
Northwestern Medicine scientists have discovered the genetic driver of a rare and lethal childhood leukemia and identified a targeted molecular therapy that halts the proliferation of leukemic...
Obesity-associated protein could be linked to leukemia development
Source: Biology / Biochemistry News From Medical News Today [2016.12.30]
Cancer researchers at the University of Cincinnati (UC) College of Medicine have found an obesity-associated protein's role in leukemia development and drug response which could lead to more...
Fasting could help treat most common childhood leukemia
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.12.13]
A study reveals that intermittent fasting cleared cancer cells and increased survival in mouse models of acute lymphocytic leukemia.
Side effects of leukemia drug can be safely reduced by halving dose
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.12.08]
Patients with a chronic type of leukaemia could safely reduce the side effects of life-long treatment by cutting their dose in half, according to the results of a University of Liverpool led study...
Therapeutic Vaccine Shows 'Game-Changing' Promise Against a Leukemia
Source: MedicineNet Leukemia Specialty [2016.12.08]
Title: Therapeutic Vaccine Shows 'Game-Changing' Promise Against a Leukemia
Category: Health News
Created: 12/7/2016 12:00:00 AM
Last Editorial Review: 12/8/2016 12:00:00 AM
Published Studies Related to Sprycel (Dasatinib)
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. [2011.06]
OBJECTIVE: Nilotinib and dasatinib have not been directly compared in a randomized trial for the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase (CML-CP). The purpose of this study was to indirectly compare rates of major molecular response (MMR), progression-free survival (PFS) and overall survival by month 12 with nilotinib and dasatinib treatment of newly diagnosed CML-CP... CONCLUSION: Nilotinib was associated with significantly higher rates of MMR and overall survival compared with dasatinib by month 12 in the treatment of newly diagnosed CML-CP.
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. [2010.06.17]
BACKGROUND: Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML... CONCLUSIONS: Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long-term outcomes among patients with newly diagnosed chronic-phase CML. (ClinicalTrials.gov number, NCT00481247.) 2010 Massachusetts Medical Society
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. [2010.03]
Dasatinib 70 mg twice daily is indicated for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) intolerant or resistant to imatinib. In patients with chronic-phase chronic myelogenous leukemia, once-daily dosing has similar efficacy with improved safety, compared with twice-daily dosing...
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. [2010.02]
BACKGROUND: Dasatinib 100 mg once daily achieves intermittent BCR-ABL kinase inhibition and is approved for chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib. To better assess durability of response to and tolerability of dasatinib, data from a 2-year minimum follow-up for a dose-optimization study in chronic-phase chronic myeloid leukemia are reported here... CONCLUSIONS: Intermittent kinase inhibition can achieve rapid and durable responses, indistinguishable from those achieved with more continuous inhibition.
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. [2010.01.20]
PURPOSE: To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic myeloid leukemia in chronic phase... CONCLUSION: MMR rates at 1 year were similar with imatinib 800 mg/d and 400 mg/d, but MMR and CCyR occurred earlier in patients treated with 800 mg/d. Continued follow-up is needed to determine the clinical significance of earlier responses on high-dose imatinib.
Clinical Trials Related to Sprycel (Dasatinib)
Dasatinib in Combination With Revlimid (and Dexamethasone) [Completed]
The purpose of this study was to determine the safety and tolerability of dasatinib when
given in combination with lenalidomide and a low dose dexamethasone for the treatment of
relapsed or refractory multiple myeloma.
Evaluating the Safety of Zileuton (Zyflo�) in Combination With Dasatinib (Sprycel�) in Chronic Myelogenous Leukemia [Recruiting]
Prospective nonrandomized phase I study
The purpose of this study is to determine safety and efficacy of zileuton when added to
dasatinib in patients with chronic myelogenous leukemia (CML).
Dasatinib and Crizotinib in Advanced Cancer [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the
combination of dasatinib and crizotinib that can be given to patients with advanced cancer.
The safety of this drug combination will also be studied.
Dasatinib is designed to block certain proteins from causing cancer cells to grow out of
control. This may cause the cancer cells to die.
Crizotinib is designed to block certain abnormal genes found in cancer cells. This may
cause the cancer cells to die.
Phase I/II - Dasatinib and Decitabine [Recruiting]
The goal of this clinical research study is to learn if combining Sprycel (dasatinib) and
Dacogen (decitabine) can help to control CML. The dose level of decitabine will also be
Dasatinib is designed to block the protein that is responsible for chronic myeloid leukemia.
Decitabine is designed to affect the mechanism that cells use to control the expression of
certain genes, some of which are important in the progression of CML.
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors [Completed]
Reports of Suspected Sprycel (Dasatinib) Side Effects
Pleural Effusion (175),
Neoplasm Malignant (71),
Anaemia (47), more >>